CAMLAW: Complementary and Alternative Medicine Law Blog

International Esthetics Show

Coming to Orlando in October.

The International Esthetics, Cosmetics & Spa Conferences (IECSC) gives estheticians, cosmeticians, spa and salon owners, massage therapists, makeup artists, medical estheticians, and doctors around the world a chance to improve their services by offering them superior education and the largest display of professional products. All companies exhibiting sell or distribute products or services to spas/salons. The products presented at the conference are not available in supermarkets or department stores.

The show runs October 7th - 9th. Show times will be:
October 7th from 11 AM - 6 PM
October 8th from 10 AM - 6 PM
October 9th from 10 AM - 4 PM

The MIAJ(TM) Skincare line will be located in booths 653-655, where orders will be accepted during the show.

MIAJ(TM) has received a positive response from its recent ad in American Spa magazine. MIAJ(TM) will also be appearing in the October 2006 issue of Allure magazine. The full line of MIAJ(TM) can be seen at

IGI continues to see a growth in development and sales of products using the company's patented Novasome(R) lipid vesicle encapsulation technology to the Asian-Pacific and US markets. IGI anticipates additional production and revenues from these new customers to begin in the fourth quarter of 2006.

IGI is a company committed to growth by applying proprietary technologies to achieve cost-effective solutions for varied customer needs. IGI offers the patented Novasome(R) lipid vesicle encapsulation technology which contributes value-added qualities to cosmetics, skin care products, dermatological formulations and other consumer products, providing improved dermal absorption, low potential for irritations, controlled and sustained release as well as improved stability. IGI has licensed Novasome(R) lipid vesicle encapsulation technology to leading global dermatological and skin care companies including Johnson & Johnson Consumer Products, Inc., Estee Lauder Companies, Chattem Inc., Genesis Pharmaceutical, Inc. and Apollo Pharmaceutical, Inc. IGI sub-licensed the rights to obtain FDA approval for and market IGI's PTH (1-34) compound using Novasome(R) lipid vesicle encapsulation technology for psoriasis, which is being reformulated for Phase II clinical trials, to Manhattan Pharmaceuticals, Inc. IGI is also exploring the licensing of the topical PTH (7-34) compound for the prevention/treatment of chemotherapy induced-alopecia in patients undergoing chemotherapy. IGI develops products that diminish the visual affects of aging. These products can be found at The cosmetics and skin care industry is experiencing tremendous growth, with global sales of anti-aging treatments alone topping out at $9.9 billion in 2004, up 71% from the previous year (Source: TIME magazine). Globally, the skin care market is over $50 billion. IGI is also developing topical products for localized pain.

This report contains forward-looking statements relating to IGI's hopes and expectations for the future. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as "will," "possible," "one time," "provides an opportunity," "continue" and similar expressions are intended to identify forward-looking statements. Such statements involve a number of risks and uncertainties and actual future events and results could differ materially from those indicated by such forward-looking statements due to general economic conditions, and the risk factors detailed in IGI's periodic reports and registration statements filed with the Securities and Exchange Commission.

Trackbacks (0) Links to blogs that reference this article Trackback URL
Comments (0) Read through and enter the discussion with the form at the end

Michael H. Cohen, Esq.; 468 North Camden Dr. | Beverly Hills, California 90210 | 310-844-3173